Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa in Patients With Non-classic Pompe Disease Aged >= 5 Years

U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07652814) titled 'Safety and Efficacy of Avalglucosidase Alfa in Patients With Non-classic Pompe Disease Aged >= 5 Years' on Nov. 01, 2022.

Brief Summary: The goal of this clinical trial is to study the efficacy and safety of treatment with avalglucosidase alfa in patients with late onset Pompe disease that previously deteriorated on alglucosidase alfa.

The main question it aims to answer is:

* Is switching to avalglucosidase alfa in late-onset Pompe patients deteriorating on alglucosidase alfa safe?

* Is switching to avalglucosidase alfa in late-onset Pompe patients deteriorating on alglucosidase alfa potentially more effective?

Participants wil...